---
title: "MAIA Biotechnology 6M 2026: Net loss $(14.31M), Diluted EPS $(0.27) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295412949.md"
description: "MAIA Biotechnology reported a $14.31M net loss for H1 2026, widening from $9.86M in 2025, with diluted EPS of $(0.27). The company remains pre-revenue. Clinically, it advanced Phase 2/3 trials for ateganosine in lung cancer, achieving a 90.5% disease control rate in interim results. Supported by a $33M equity offering, MAIA secured FDA clearance and partnerships with Regeneron, BeOne, and Roche, while planning new Phase 2 trials in hepatocellular, colorectal, and small cell lung cancers."
datetime: "2026-08-10T13:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295412949.md)
  - [en](https://longbridge.com/en/news/295412949.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295412949.md)
generator: "portal-rs"
---

# MAIA Biotechnology 6M 2026: Net loss $(14.31M), Diluted EPS $(0.27) — 10-Q Summary

MAIA Biotechnology, Inc. reported a net loss of $(14.31M) for the six months ended June 30, 2026, compared with a $(9.86M) loss for the six months ended June 30, 2025. The company remains pre-revenue; diluted loss per share narrowed to $(0.27) for the six months ended June 30, 2026 from $(0.34) a year earlier.

**Financial Highlights**

-   Revenue: No revenue reported for the periods presented (company continues to be pre-revenue).
-   Net income: $(14.31M) net loss for six months ended Jun 30, 2026, versus $(9.86M) for six months ended Jun 30, 2025 (loss increased (45%) year over year).
-   Diluted EPS: $(0.27) for six months ended Jun 30, 2026, versus $(0.34) for six months ended Jun 30, 2025.

**Business Highlights**

-   Clinical progress: Initiated and expanded Phase 2 (THIO-101) and Phase 3 (THIO-104) trials of ateganosine in third-line non-small cell lung cancer with U.S. site activations.
-   Regulatory & partnerships: FDA IND amendment cleared; supply agreements in place with Regeneron, BeOne and Roche to support checkpoint inhibitor combination studies.
-   Clinical data momentum: Part C interim results showed a 90.5% disease control rate (19/21) and several earlier patients with more than two-year overall survival, supporting regulatory discussions.
-   Funding & operations: A $33M equity offering in March 2026 funded the pivotal Phase 3 and expansion activities, enabling increased clinical enrollment and manufacturing updates.
-   Pipeline expansion: Plans to start Phase 2 trials in hepatocellular carcinoma, colorectal cancer and small cell lung cancer, and to develop second-generation molecules with Phase 1 starts planned.

Original SEC Filing: MAIA Biotechnology, Inc. \[ MAIA \] - 10-Q - Aug. 10, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [MAIA.US](https://longbridge.com/en/quote/MAIA.US.md)
- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)
- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Ramiro Guerrero Buys 46,620 Shares](https://longbridge.com/en/news/297763003.md)
- [MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Buys 8,931 Shares of Stock](https://longbridge.com/en/news/297701042.md)
- [MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Ramiro Guerrero Purchases 78,239 Shares](https://longbridge.com/en/news/297699634.md)
- [Maia Bio director Ramiro Guerrero buys 133,790 shares worth $185,114.90](https://longbridge.com/en/news/297693795.md)
- [Simcere Zaiming licenses SIM0660 to Roche in deal worth up to $1.53 billion](https://longbridge.com/en/news/297652647.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**